Clinical Trials at UT MD Anderson Cancer Center
As of July 2026, 60 paid clinical trials are recruiting at UT MD Anderson Cancer Center, located at 1515 HOLCOMBE BLVD UNIT 72, HOUSTON, TX 77030-4009, phone (713) 792-6327 in Houston, Texas. Active studies at this site cover conditions such as Breast Cancer, Acute Myeloid Leukemia and Advanced Solid Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
60 clinical trials at UT MD Anderson Cancer Center
·Clear filters·↓ Download CSVA Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
About research studies in Houston
Houston has approximately 3,031 recruiting research studies across a wide range of therapeutic areas. Texas hosts major cancer and cardiovascular research centers including MD Anderson Cancer Center, Baylor College of Medicine, UT Southwestern Medical Center, and the Texas Medical Center — the largest medical complex in the world.
Common conditions studied in Houston
- Breast Cancer (79 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Acute Myeloid Leukemia (56 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Advanced Solid Tumor (53 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Ovarian Cancer (48 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Colorectal Cancer (46 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Prostate Cancer (42 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
Leading research sponsors in Houston
- M.D. Anderson Cancer Center
- The University of Texas Health Science Center, Houston
- Baylor College of Medicine
- AstraZeneca
- The Methodist Hospital Research Institute
Local regulations and guidelines
Clinical trials in Texas are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Trials run in Texas must also comply with the Texas Medical Privacy Act (TMPA), which extends federal HIPAA protections to a broader range of entities handling participant data.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Houston. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Houston
Hipa.ai aggregates every recruiting study in Houston from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Houston?
There are approximately 3,031 recruiting clinical trials in Houston, Texas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Houston pay participants?
Most recruiting trials in Houston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Houston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Houston?
The most common conditions under active study in Houston include Breast Cancer (79), Acute Myeloid Leukemia (56), Advanced Solid Tumor (53), Ovarian Cancer (48), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Houston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Houston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Houston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Houston?
Recruiting research sites in Houston include MD Anderson Cancer Center, M D Anderson Cancer Center, Baylor College of Medicine, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Houston right now?
The largest active categories in Houston are Cancer & tumors (1,184), Neurology & pain (144), Diabetes & metabolic (104). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of UT MD Anderson Cancer Center?
UT MD Anderson Cancer Center is located at 1515 HOLCOMBE BLVD UNIT 72, HOUSTON, TX 77030-4009. Use the Google Maps link in the intro above to get directions.
How do I contact UT MD Anderson Cancer Center?
You can reach UT MD Anderson Cancer Center by phone at (713) 792-6327. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.